A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (NCT05789082)
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- City of Hope National Medical Center — Duarte, California
- City of Hope - Seacliff — Huntington Beach, California
- City of Hope at Irvine Lennar — Irvine, California
- UCSD Moores Cancer Center — La Jolla, California
- City of Hope - Long Beach Elm — Long Beach, California
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists - SOUTH - SCRI - PPDS — Fort Myers, Florida
- Florida Cancer Specialists - NORTH - SCRI - PPDS — St. Petersburg, Florida
- Florida Cancer Specialists - EAST - SCRI - PPDS — West Palm Beach, Florida
- NYU Langone Hospital - Long Island — Mineola, New York
- NYU Cancer Center — New York, New York
- Mount SInai Medical Center — New York, New York
- Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
- MD Anderson Cancer Center — Houston, Texas
- Oncology & Hematology Associates of Southwest Virginia, Inc — Blacksburg, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Hospital Britanico — Buenos Aires,
- Clinica Adventista Belgrano — Ciudad Autonoma Buenos Aires,
- Centro Oncologico Riojano Integral (CORI) — La Rioja,
- Concord Repatriation General Hospital — Concord, New South Wales
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Alfred Health — Melbourne, Victoria
- Cliniques Universitaires St-Luc — Brussels,
- Jessa Zkh (Campus Virga Jesse) — Hasselt,
- Clinique Ste-Elisabeth — Namur,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.